Nizar M. Tannir - Concepedia

Author

Nizar M. Tannir

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Chantale Bernatchez, Gail L. Brown, Irwin Davidson, N M Tannir, N Tannir, N. M. Tannir, N. Tannir, N.M. Tannir, NIZAR TANNIR, Nazir M. Tannir

Publications

31K

Citations

H-Index

180

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute Institut Gustave Roussy Bristol-Myers Squibb (United States)

About

Nizar M. Tannir is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	53	141	11K
2	Health Sciences	16	23	946
3	Public Health	5	5	1.9K
4	Education	1	1	68
5	Engineering	1	1	13

Nizar M. Tannir

295

Publications

27.9K

Citations

H-Index

Page 1

	Year	Citations
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Robert J. Motzer, Nizar M. Tannir, Osvaldo Arén Frontera, New England Journal of Medicine	2018	4.5K
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, The Lancet EpidemiologyCancer EpidemiologyMedicineGlobal HealthEpidemiology Of Cancer	2020	1.8K
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma Toni K. Choueiri, Bernard Escudier, Thomas Powles, New England Journal of Medicine	2015	1.2K
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial Toni K. Choueiri, Bernard Escudier, Thomas Powles, The Lancet Oncology UrologyGenitourinary CancerKidney ResearchMedicineCabozantinib Versus Everolimus	2016	927
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial Robert J. Motzer, Brian I. Rini, David F. McDermott, The Lancet Oncology UrologyGenitourinary CancerMedicinePharmacologyImmune Checkpoint Inhibitor	2019	763
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial Laurence Albigès, Nizar M. Tannir, Mauricio Burotto, ESMO Open	2020	515
Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer Ana M. Aparicio, Andrea Harzstark, Paul G. Corn, Clinical Cancer Research	2013	456
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma Lijun Zhou, Xian-De Liu, Mingli Sun, Oncogene UrologyMedicineMetronomic TherapyPharmacologyImmune Checkpoint Inhibitor	2015	386
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial Nizar M. Tannir, Eric Jonasch, Laurence Albigès, European Urology UrologyGenitourinary CancerMedicineCancer TreatmentOncology	2015	356
Reduction of Cancer-Related Fatigue With Dexamethasone: A Double-Blind, Randomized, Placebo-Controlled Trial in Patients With Advanced Cancer Sriram Yennurajalingam, Susan Frisbee‐Hume, J. Lynn Palmer, Journal of Clinical Oncology	2013	334

Page 1